{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/a4c5de36-8260-4222-8e38-ff997dc73436/6363e229a8f89a0011d903a7?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"The Companies and Markets show: GSK, Private Equity Trusts, and two more hot Aim stocks","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61b9b44742e856e989985776/1667489937453-00cc8b8ae8c5a109712395dcb149a24e.jpeg?height=200","description":"<p>On this week's episode, Dan Jones welcomes Jennifer Johnson to talk GlaxoSmithKline (GSK) - they've made a good start to life post Haleon split, but are they a one-trick pony at the moment?</p><p><br></p><p>Then Mark Robinson dives back into the Aim 100, with two more interesting stocks from our special review of the top 100 companies in Aim (by market capitalisation).</p><p><br></p><p>And finally, Val Cipriani makes her podcast debut with a look at private equity trusts.</p><p><br></p><p>Dan Jones hosts Jennifer Johnson, Val Cipriani and Mark Robinson.</p><p><br></p><p>-</p><p><br></p><p><a href=\"https://tillitinvest.com/\" rel=\"noopener noreferrer\" target=\"_blank\">This podcast is sponsored by TILLIT</a>. TILLIT is the investment platform for investors who want to make better investment decisions. Invest in a curated selection of funds, investment trusts and ETFs and get expert insights on each and every one.</p>","author_name":"Investors' Chronicle"}